Breaking News Instant updates and real-time market news.

MYL

Mylan

$31.79

-0.21 (-0.66%)

10:59
08/09/17
08/09
10:59
08/09/17
10:59

Mylan: FDA delays 'administrative,' 'not the science'

  • 09

    Aug

  • 03

    Sep

  • 09

    Oct

MYL Mylan
$31.79

-0.21 (-0.66%)

08/09/17
BMOC
08/09/17
NO CHANGE
BMOC
Outperform
Mylan generic push outs 'disappointing, but not surprising,' says BMO Capital
BMO Capital analyst Gary Nachman said expectations for Mylan have been "very low" even before the company reported on its "challenging" second quarter. While the push out of generic Advair and Copaxone into 2018 is a disappointment, he believes this possibility has been the consensus view among investors. Nachman maintains an Outperform rating on Mylan shares.
08/09/17
WELS
08/09/17
NO CHANGE
Target $30
WELS
Market Perform
Mylan results, outlook confirm cautious stance on generics, says Wells Fargo
Wells Fargo analyst David Maris, who notes that he was cautious on the generic sector heading into Mylan's quarterly report, said the results and outlook communicated by the company have confirmed his caution. Maris, who lowered his 2017 and 2018 estimates for Mylan after the company cut its guidance and said they have elected to defer all major U.S. launches from their FY17 financial view, lowered his price target on the stock to $30 from $34.50. He keeps a Market Perform rating on Mylan.
08/09/17
RAJA
08/09/17
NO CHANGE
RAJA
Mylan shares more than reflect reset expectations, says Raymond James
Raymond James believes Mylan shares more than adequately reflect the magnitude of reset expectations and is confident, if management can gain confidence in revised 2018 earnings guidance, the stock can quickly bounce back to the mid-$30 range.
07/18/17
WELS
07/18/17
NO CHANGE
WELS
Market Perform
Novartis report has cautious read-through for Mylan, Teva, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis' (NVS) Sandoz unit is one of the world's largest generic drug makers and he believes the proper read-through from its report is that the U.S. generic market remains challenging and that investors should remain cautious on the generics space. Maris, who said he would not be surprised to see Mylan (MYL) or Teva (TEVA) weaker following Novartis' report, keeps Market Perform ratings on those two names.

TODAY'S FREE FLY STORIES

WERN

Werner

$30.95

-0.1 (-0.32%)

13:27
08/17/17
08/17
13:27
08/17/17
13:27
Hot Stocks
Werner CEO says business has been improving throughout the year »

The trucking firm's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

13:25
08/17/17
08/17
13:25
08/17/17
13:25
General news
U.S. VIX equity volatility surged 26% to 14.88 highs »

U.S. VIX equity…

13:25
08/17/17
08/17
13:25
08/17/17
13:25
Conference/Events
SEC holds a closed commission meeting »

Closed Commission Meeting…

WMT

Wal-Mart

$79.18

-1.7998 (-2.22%)

13:24
08/17/17
08/17
13:24
08/17/17
13:24
Recommendations
Wal-Mart analyst commentary  »

Wal-Mart posted good…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 16

    Nov

  • 20

    Feb

ADP

ADP

$111.10

-0.48 (-0.43%)

13:21
08/17/17
08/17
13:21
08/17/17
13:21
Recommendations
ADP analyst commentary  »

ADP will have difficulty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

NAK

Northern Dynasty

$1.56

0.065 (4.36%)

13:20
08/17/17
08/17
13:20
08/17/17
13:20
Options
Call buyers back in Northern Dynasty Minerals »

Call buyers back in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$11.55

-0.035 (-0.30%)

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Upgrade
Celestica rating change  »

Follow-up: Celestica…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

, AZN

AstraZeneca

$29.12

-0.0637 (-0.22%)

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Hot Stocks
Breaking Hot Stocks news story on Tesaro, AstraZeneca »

Tesaro drops 2% after FDA…

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

AZN

AstraZeneca

$29.12

-0.0637 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 08

    Sep

  • 08

    Sep

$NSD

NASDAQ Market Internals

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$29.11

-0.07 (-0.24%)

13:16
08/17/17
08/17
13:16
08/17/17
13:16
Hot Stocks
FDA posts approval of new dosage form for AstraZeneca's Lynparza 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Sep

  • 08

    Sep

$NYE

NYSE Market Internals

13:16
08/17/17
08/17
13:16
08/17/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$19.72

-1.17 (-5.60%)

, LVLT

Level 3

$53.45

-1.73 (-3.14%)

13:13
08/17/17
08/17
13:13
08/17/17
13:13
Hot Stocks
CenturyLink says working to finalize Level 3 deal by end of Q3 »

CenturyLink (CTL) said in…

CTL

CenturyLink

$19.72

-1.17 (-5.60%)

LVLT

Level 3

$53.45

-1.73 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$19.73

-1.16 (-5.55%)

, LVLT

Level 3

$53.45

-1.73 (-3.14%)

13:12
08/17/17
08/17
13:12
08/17/17
13:12
Hot Stocks
Breaking Hot Stocks news story on CenturyLink, Level 3 »

CenturyLink says working…

CTL

CenturyLink

$19.73

-1.16 (-5.55%)

LVLT

Level 3

$53.45

-1.73 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$111.10

-0.48 (-0.43%)

13:10
08/17/17
08/17
13:10
08/17/17
13:10
Options
ADP attracts put buyers as shares come under fire »

ADP attracts put buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

ADOM

Adomani

$12.86

0.86 (7.17%)

, VLKAY

Volkswagen

$31.10

0.19 (0.61%)

13:06
08/17/17
08/17
13:06
08/17/17
13:06
Hot Stocks
Adomani sees $2.9B in settlement funds from Volkswagen »

Adomani (ADOM) announced…

ADOM

Adomani

$12.86

0.86 (7.17%)

VLKAY

Volkswagen

$31.10

0.19 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$11.89

-0.05 (-0.42%)

13:05
08/17/17
08/17
13:05
08/17/17
13:05
Options
Horizon Pharma call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$11.50

-0.08 (-0.69%)

13:04
08/17/17
08/17
13:04
08/17/17
13:04
Upgrade
Celestica rating change  »

Celestica upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDVX

Medovex

$0.95

0.05 (5.56%)

12:55
08/17/17
08/17
12:55
08/17/17
12:55
Hot Stocks
Medovex names Charlie Farrahar as CFO »

Medovex reported it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$33.20

-0.16 (-0.48%)

12:53
08/17/17
08/17
12:53
08/17/17
12:53
Hot Stocks
FDA posts approval of Pfizer's biologic license qpplication for Besponsa 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 08

    Sep

  • 08

    Sep

  • 13

    Sep

NADL

North Atlantic Drilling

$1.44

-0.075 (-4.97%)

12:50
08/17/17
08/17
12:50
08/17/17
12:50
Options
Notable put spread in North Atlantic Drilling »

Notable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

12:45
08/17/17
08/17
12:45
08/17/17
12:45
General news
Breaking General news story  »

Dallas Federal Reserve…

HRB

H&R Block

$30.21

-0.53 (-1.72%)

12:40
08/17/17
08/17
12:40
08/17/17
12:40
Options
Higher option volume in H&R Block driven by call buying »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 14

    Sep

EXPE

Expedia

$148.78

1.72 (1.17%)

12:35
08/17/17
08/17
12:35
08/17/17
12:35
Options
Expedia put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:35
08/17/17
08/17
12:35
08/17/17
12:35
General news
Treasury Option Action: call buying at the long-end »

Treasury Option Action:…

ADP

ADP

$111.10

-0.48 (-0.43%)

12:32
08/17/17
08/17
12:32
08/17/17
12:32
Hot Stocks
Chapman says making dollar going against Ackman feels as good as $10 »

Robert Chapman of Chapman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.